The risk of infections with biologic therapies for rheumatoid arthritis

Seminars in Arthritis and Rheumatism

Volumn 39, Issue 5, 2010, Pages 327-346

  Furst, Daniel E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Abatacept; Adalimumab; Anakinra; Arthritis; Etanercept; Infection; Infliximab; Rheumatoid; Rituximab; TNF inhibitor; Tuberculosis

Indexed keywords

ABATACEPT; ADALIMUMAB; ANALGESIC AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; INFLUENZA VACCINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PNEUMOCOCCUS VACCINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB;

BACTERIAL INFECTION; BIBLIOGRAPHIC DATABASE; BIOLOGICAL THERAPY; BRONCHITIS; BURSITIS; CELLULITIS; CLINICAL TRIAL; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; HERPES ZOSTER; HISTOPLASMOSIS; HUMAN; INFECTION RISK; INFLUENZA; LUNG ASPERGILLOSIS; MYCOSIS; PERITONITIS; PNEUMONIA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PYELONEPHRITIS; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEPSIS; SKIN INFECTION; SOFT TISSUE INFECTION; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; TREATMENT DURATION; TUBERCULOSIS; URINARY TRACT INFECTION; VIRUS INFECTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BACTERIAL INFECTIONS; BIOLOGICAL THERAPY; HUMANS; INFECTION; OPPORTUNISTIC INFECTIONS; TUMOR NECROSIS FACTOR-ALPHA; VIRUS DISEASES;

EID: 77949571175     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2008.10.002     Document Type: Review

References (150)

1. Ellerin T., Rubin R.H., Weinblatt M.E. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003, 48:3013-3022.
2. Netea M.G., Radstake T., Joosten L.A., van der Meer J.W., Barrera P., Kullberg B.J. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum 2003, 48:1853-1857.
3. Popa C., Netea M.G., Barrera P., Radstake T.R., van Riel P.L., Kullberg B.J., et al. Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy. Cytokine 2005, 30:72-77.
4. Saliu O.Y., Sofer C., Stein D.S., Schwander S.K., Wallis R.S. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006, 194:486-492.
5. Burger D., Dayer J.M., Palmer G., Gabay C. Is IL-1 a good therapeutic target in the treatment of arthritis?. Best Pract Res Clin Rheumatol 2006, 20:879-896.
6. Janeway C.A., Travers P., Walport M., Capra J.D. Immunobiology. The immune system in health and disease 1999, Elsevier Science, London. 4th ed.
7. Mikuls T.R. Co-morbidity in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003, 17:729-752.
8. Hernandez-Cruz B., Cardiel M.H., Villa A.R., Alcocer-Varela J. Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study. J Rheumatol 1998, 25:1900-1907.
9. van der Veen M.J., van der H.A., Kruize A.A., Bijlsma J.W. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 1994, 53:224-228.
10. Cobb S., Anderson F., Bauer W. Length of life and cause of death in rheumatoid arthritis. N Engl J Med 1953, 249:553-556.
11. Doran M.F., Crowson C.S., Pond G.R., O'Fallon W.M., Gabriel S.E. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002, 46:2287-2293.
12. Hughes L.B., Criswell L.A., Beasley T.M., Edberg J.C., Kimberly R.P., Moreland L.W., et al. Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun 2004, 5:641-647.
13. Alldred A. Etanercept in rheumatoid arthritis. Exp Opin Pharmacother 2001, 2:1137-1148.
14. ENBREL Amgen and Wyeth Pharmaceuticals Inc., Accessed on 22-8-2007. http://www.enbrel.com/2007.
15. Markham A., Lamb H.M. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000, 59:1341-1359.
16. REMICADE® (infliximab). Prescribing information 2007, Centocor Inc., Centocor Inc, Malvern (PA).
17. Machold K.P., Smolen J.S. Adalimumab-a new TNF-α antibody for treatment of inflammatory joint disease. Exp Opin Biol Ther 2003, 3:351-360.
18. ®) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:889-894.
19. Genovese M.C., Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002, 46:1443-1450.
20. Klareskog L., van der Heijde D., de Jager J.P., Gough A., Kalden J., Malaise M., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004, 363:675-681.
21. van Riel P.L., Taggart A.J., Sany J., Gaubitz M., Nab H.W., Pedersen R., et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 2006, 65:1478-1483.
22. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000, 343:1594-1602.
23. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Furst D., Weisman M.H., et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004, 50:1051-1065.
24. St Clair E.W., van der Heijde D.M., Smolen J.S., Maini R.N., Bathon J.M., Emery P., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004, 50:3432-3443.
25. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003, 48:35-45.
26. Furst D.E., Schiff M.H., Fleischmann R.M., Strand V., Birbara C.A., Compagnone D., et al. Adalimumab, a fully human anti tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003, 30:2563-2571.
27. van de Putte L.B., Atkins C., Malaise M., Sany J., Russell A.S., van Riel P.L.C.M., et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004, 63:508-516.
28. Keystone E.C., Kavanaugh A.F., Sharp J.T., Tannenbaum H., Hua Y., Teoh L.S., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004, 50:1400-1411.
29. Breedveld F.C., Weisman M.H., Kavanaugh A.F., Cohen S.B., Pavelka K., van Vollenhoven R., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006, 54:26-37.
30. Weinblatt M.E., Keystone E.C., Furst D.E., Kavanaugh A.F., Chartash E.K., Segurado O.G. Long-term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4-year extended study. Ann Rheum Dis 2005, 65:753-759.
31. Cairns A.P., Taggart A.J. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland. Ulster Med J 2002, 71:101-105.
32. Maillard H., Ornetti P., Grimault L., Ramon J.F., Ducamp S.M., Saidani T., et al. Severe pyogenic infections in patients taking infliximab: a regional cohort study. Jt Bone Spine 2005, 72:330-334.
33. Hansen K.E., Cush J., Singhal A., Cooley D.A., Cohen S., Patel S.R., et al. The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. Arthritis Rheum 2004, 51:228-232.
34. Vander Cruyssen B., Van Looy S., Wyns B., Westhovens R., Durez P., van den Bosch F., et al. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. Arthritis Res Ther 2006, 8:R112.
35. Kroesen S., Widmer A.F., Tyndall A., Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-α therapy. Rheumatology (Oxford) 2003, 42:617-621.
36. Cabou C., Bagheri H., Cantagrel A., Mazieres B., Montastruc J.L. [Retrospective analysis of adverse effects of infliximab in a hospital rheumatology service]. Therapie 2003, 58:457-462.
37. Curtis J.R., Patkar N., Xie A., Martin C., Allison J.J., Saag M., et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007, 56:1125-1133.
38. Listing J., Strangfeld A., Kary S., Rau R., von H.U., Stoyanova-Scholz M., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005, 52:3403-3412.
39. Askling J., Fored C.M., Brandt L., Baecklund E., Bertilsson L., Feltelius N., et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF- antagonists. Ann Rheum Dis 2007, 66:1339-1344.
40. Dixon W.G., Watson K., Lunt M., Hyrich K.L., Silman A.J., Symmons D.P. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006, 54:2368-2376.
41. Dixon W.G., Symmons D.P., Lunt M., Watson K.D., Hyrich K.L., Silman A.J. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007, 56:2896-2904.
42. Tubach F., Ravaud P., Salmon-Céron D., Petitpain N., Brocq O., Grados F., et al. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-α antagonists. Clin Infect Dis 2006, 43:e95-e100.
43. Bassetti S., Wasmer S., Hasler P., Vogt T., Nogarth D., Frei R., et al. Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti-tumor necrosis factor-alpha treatment. J Rheumatol 2005, 32:2125-2129.
44. Yim K., Nazeer S.H., Kiska D., Rose F.B., Brown D., Cynamon M.H. Recurrent Mycobacterium xenopi infection in a patient with rheumatoid arthritis receiving etanercept. Scand J Infect Dis 2004, 36:150-154.
45. Thomas J.E., Taoka C.R., Gibbs B.T., Fraser S.L. Fatal pulmonary Mycobacterium abscessus infection in a patient using etanercept. Hawaii Med J 2006, 65:12-15.
46. Manadan A.M., Block J.A., Sequeira W. Mycobacteria tuberculosis peritonitis associated with etanercept therapy. Clin Exp Rheumatol 2003, 21:526.
47. Mufti A.H., Toye B.W., Mckendry R.R., Angel J.B. Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use. Diagn Microbiol Infect Dis 2005, 53:233-238.
48. Imaizumi K., Sugishita M., Usui M., Kawabe T., Hashimoto N., Hasegawa Y. Pulmonary infectious complications associated with anti-TNFalpha therapy (infliximab) for rheumatoid arthritis. Intern Med 2006, 45:685-688.
49. Boulman N., Rozenbaum M., Slobodin G., Rosner I. Mycobacterium fortuitum infection complicating infliximab therapy in rheumatoid arthritis. Clin Exp Rheumatol 2006, 24:723.
50. Efde M.N., Houtman P.M., Spoorenberg J.P., Jansen T.L. Tonsillar tuberculosis in a rheumatoid arthritis patient receiving anti-TNFalpha (adalimumab) treatment. Neth J Med 2005, 63:112-114.
51. Gutierrez-Macias A., Lizarralde-Palacios E., Martinez-Odriozola P., Miguel-de l V. Tuberculous peritonitis in a patient with rheumatoid arthritis treated with adalimumab. Clin Rheumatol 2007, 26:452-453.
52. Pagliano P., Attanasio V., Fusco U., Mohamed D.A., Rossi M., Faella F.S. Does etanercept monotherapy enhance the risk of Listeria monocytogenes meningitis?. Ann Rheum Dis 2004, 63:462-463.
53. Schett G., Herak P., Graninger W., Smolen J.S., Aringer M. Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature. J Clin Microbiol 2005, 43:2537-2541.
54. Rachapalli S., O'Daunt S. Septic arthritis due to Listeria monocytogenes in a patient receiving etanercept. Arthritis Rheum 2005, 52:987.
55. Bowie V.L., Snella K.A., Gopalachar A.S., Bharadwaj P. Listeria meningitis associated with infliximab. Ann Pharmacother 2004, 38:58-61.
56. Glück T., Linde H.J., Scholmerich J., Muller-Ladner U., Fiehn C., Bohland P. Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum 2002, 46:2255-2257.
57. Borras-Blasco J., Nunez-Cornejo C., Gracia-Perez A., Rosique-Robles J.D., Castera M.D., Viosca E., et al. Parapharyngeal abscess in a patient receiving etanercept. Ann Pharmacother 2007, 41:341-344.
58. Harney S., O'Shea F.D., FitzGerald O. Peptostreptococcal pericarditis complicating anti-tumour necrosis factor alpha treatment in rheumatoid arthritis. Ann Rheum Dis 2002, 61:653-654.
59. Elwood R.L., Pelszynski M.M., Corman L.I. Multifocal septic arthritis and osteomyelitis caused by group A Streptococcus in a patient receiving immunomodulating therapy with etanercept. Pediatr Infect Dis J 2003, 22:286-288.
60. Wondergem M.J., Voskuyl A.E., van Agtmael M.A. A case of legionellosis during treatment with a TNFalpha antagonist. Scand J Infect Dis 2004, 36:310-311.
61. Smith D., Letendre S. Viral pneumonia as a serious complication of etanercept therapy. Ann Intern Med 2002, 136:174.
62. Killingley B., Carpenter V., Flanagan K., Pasvol G. Pneumococcal meningitis and etanercept-chance or association?. J Infect 2005, 51:E49-E51.
63. Gerster J.C., Dudler J. Cellulitis caused by Capnocytophaga cynodegmi associated with etanercept treatment in a patient with rheumatoid arthritis. Clin Rheumatol 2004, 23:570-571.
64. Katsarolis I., Tsiodras S., Panagopoulos P., Giannitsioti E., Skarantavos G., Ioannidis T., et al. Septic arthritis due to Salmonella enteritidis associated with infliximab use. Scand J Infect Dis 2005, 37:304-305.
65. Sipsas N.V., Papaparaskevas J., Stefanou I., Kalatzis K., Vlachoyiannopoulos P., Avlamis A. Septic arthritis due to Roseomonas mucosa in a rheumatoid arthritis patient receiving infliximab therapy. Diagn Microbiol Infect Dis 2006, 55:343-345.
66. Jimenez F.G., Colmenero J.D., Irigoyen M.V. Reactivation of brucellosis after treatment with infliximab in a patient with rheumatoid arthritis. J Infect 2005, 50:370-371.
67. Fabre S., Gibert C., Lechiche C., Jorgensen C., Sany J. Primary cutaneous Nocardia otitidiscaviarum infection in a patient with rheumatoid arthritis treated with infliximab. J Rheumatol 2005, 32:2432-2433.
68. De Rosa F.G., Shaz D., Campagna A.C., Dellaripa P.E., Khettry U., Craven D.E. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case?. Infect Control Hosp Epidemiol 2003, 24:477-482.
69. Kirchgatterer A., Weber T., Hinterreiter M., Knoflach P., Allerberger F. Haemorrhagic colitis due to Escherichia coli O103:H2 associated with infliximab therapy in a patient with rheumatoid arthritis. Rheumatology (Oxford) 2002, 41:355-356.
70. Montero J.A., Ruiz-Moreno J.M., Rodriguez A.E., Ferrer C., Sanchis E., Alio J.L. Endogenous endophthalmitis by Propionibacterium acnes associated with leflunomide and adalimumab therapy. Eur J Opthalmol 2006, 16:343-345.
71. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285.
72. Fleischmann R., Stern R., Iqbal I. Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis. Exp Opin Biol Ther 2004, 4:1333-1344.
73. Fleischmann R.M., Tesser J., Schiff M.H., Schechtman J., Burmester G.R., Bennett R., et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:1006-1012.
74. Ruderman E.M., Pope R.M. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis. Arthritis Res Ther 2005, 7(Suppl 2):S21-S25.
75. ORENCIA® (abatacept) 2007, Bristol-Meyers Squibb Company, Bristol-Meyers Squibb Company, Princeton (NJ).
76. Kremer J.M., Westhovens R., Leon M., Di Giorgio E., Alten R., Steinfeld S., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003, 349:1907-1915.
77. Genovese M.C., Becker J.C., Schiff M., Luggen M., Sherrer Y., Kremer J., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005, 353:1114-1123.
78. Kremer J.M., Genant H.K., Moreland L.W., Russell A.S., Emery P., Abud-Mendoza C., et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006, 144:865-876.
79. Bigbee C.L., Gonchoroff D.G., Vratsanos G., Nadler S.G., Haggerty H.G., Flynn J.L. Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice. Arthritis Rheum 2007, 56:2557-2565.
80. Schiff M., Keiserman M., Codding C., Songcharoen S., Berman A., Nayiager S., et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008, 67:1096-1103.
81. Weinblatt M., Combe B., Covucci A., Aranda R., Becker J.C., Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006, 54:2807-2816.
82. Weinblatt M., Schiff M., Goldman A., Kremer J., Luggen M., Li T., et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007, 66:228-234.
83. Salliot C., Gossec L., Dougados M. Rituximab abatacept and anakinra do not increase the risk of serious infections: a meta-analysis of published randomised clinical trials. Ann Rheum Dis 2007, 66(Suppl II):436.
84. Simon T.A., Smitten A., Meng M., Franklin J., Askling J., Lacaille D., et al. Serious infections in the rheumatoid arthritis abatacept clinical development program: an updated epidemiological assessment. Ann Rheum Dis 2007, 66(suppl II):438.
85. Dass S., Vital E.M., Emery P. Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis. Exp Opin Pharmacother 2006, 7:2559-2570.
86. Emery P., Fleischmann R., Filipowicz-Sosnowska A., Schechtman J., Szczepañski L., Kavanaugh A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006, 54:1390-1400.
87. Edwards J.C., Szczepañski L., Szechiñski J., Filipowicz-Sosnowska A., Emery P., Close D.R., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581.
88. Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled. Phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54:2793-2806.
89. Emery P, Sheeran T, Lehane PB, Saíedabadi N, Shaw TM. Efficacy and safety of rituximab at 2 years following a single treatment in patients with active rheumatoid arthritis. 68th Annual Scientific Meeting, San Antonio, Texas, USA, October 16-21, 2004 [Abstract No. 1762].
90. Emery P., Furst D.E., Ferraccioli G., Udell J., van Vollenhoven R.F., Rowe K.A., et al. Long-term efficacy and safety of a repeat treatment course of rituximab in RA patients with an inadequate response to disease-modifying anti-rheumatic drugs. Arthritis Rheum 2006, 65(Suppl II):58. [Abstract No. OP0017].
91. Keystone E., Fleischmann R., Emery P., Furst D., van Vollenhoven R.F., Bathon J., et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis. Arthritis Rheum 2007, 56:3896-3908.
92. van Vollenhoven R., Emery P., Bingham C., Keystone E., Greenwald M., Morelan L.W., et al. Long-term safety data from extended follow-up and repeat use of rituximab in rheumatoid arthritis. Ann Rheum Dis 2007, 66(Suppl II):88.
93. Genovese M.C., Breedveld F.C., Emery P., Moreland L.W., Keystone E.C., Matteson E.L., et al. Safety of TNF inhibitors and non-biologic dmards in rheumatoid arthritis patients previously treated with rituximab. Arthritis Rheum 2007, 56(Suppl 9):S150.
94. Kimby E. Tolerability and safety of rituximab (MabThera(R)). Cancer Treat Rev 2005, 31:456-473.
95. Mohrbacher A. B cell non-Hodgkin's lymphoma: rituximab safety experience. Arthritis Res Ther 2005, 7(Suppl 3):S19-S25.
96. Trends in tuberculosis incidence-United States, 2006. MMWR Morb Mortal Wkly Rep 2007, 56:245-250. Centers for Disease Control and Prevention (CDC).
97. Wolfe F., Michaud K., Anderson J., Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004, 50:372-379.
98. Trends in tuberculosis morbidity-United States, 1992-2002. MMWR Morb Mortal Wkly Rep 2003, 52:217-220. Centers for Disease Control and Prevention (CDC), 222.
99. Zhao S, Makuch RW, Wentworth C, Bell D, Shibata A, Wallis WJ. Incidence rates of tuberculosis in patients with rheumatoid arthritis or ankylosing spondylitis in comparison with the general population. European League Against Rheumatism 2004, Berlin, Germany, June 9-12 2004 [Abstract No. OP0040].
100. Carmona L., Hernandez-Garcia C., Vadillo C., Pato E., Balsa A., Gonzalez-Alvaro I., et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003, 30:1436-1439.
101. Askling J., Fored C.M., Brandt L., Baecklund E., Bertilsson L., Coster L., et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005, 52:1986-1992.
102. Seong S.S., Choi C.B., Woo J.H., Bae K.W., Joung C.L., Uhm W.S., et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007, 34:706-711.
103. Gomez-Reino J.J., Carmona L., Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007, 57:756-761.
104. Gómez-Reino J.J., Carmona L., Valverde V.R., Mola E.M., Montero M.D. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003, 48:2122-2127.
105. Wallis R.S., Broder M., Wong J., Lee A., Hoq L. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 2005, 41(Suppl 3):S194-S198.
106. Carmona L., Gómez-Reino J.J., Rodriguez-Valverde V., Montero D., Pascual-Gómez E., Mola E.M., et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005, 52:1766-1772.
107. Tubach F., Salmon D., Ravaud P., Pallot-Prades B., Goupille P., Schaeverbeke T., et al. Definitive results of the National French Prospective RATIO 3-year observatory on TB in patients treated with TNF blockers: the risk persists but depends on the drug. Arthritis Rheum 2007, 56:S426.
108. FDA Public Health Advisory: life-threatening brain infection in patients with systemic lupus erythematosus after Rituxan (rituximab) treatment US Food and Drug Administration, [accessed on 22-2-2008. http://www.fda.gov/cder/drug/advisory/rituximab.htm.
109. Roos J.C., Ostor A.J. Anti-tumor necrosis factor alpha therapy and the risk of JC virus infection. Arthritis Rheum 2006, 54:381-382.
110. Yamamoto M., Takahashi H., Wakasugi H., Sukawa Y., Saito M., Suzuki C., et al. Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis. Mod Rheumatol 2007, 17:72-74.
111. Bibbo C., Goldberg J.W. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 2004, 25:331-335.
112. Giles J.T., Bartlett S.J., Gelber A.C., Nanda S., Fontaine K., Ruffing V., et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 2006, 55:333-337.
113. den Broeder A.A., Creemers M.C., Fransen J., de Jong E., de Rooij D.J., Wymenga A., et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 2007, 34:689-695.
114. Dixon W., Lunt M., Watson K.D., Hyrich K. Anti-TNF therapy and the risk of serious post-operative infection: results from the BSR biologics register. Ann Rheum Dis 2007, 66(Suppl II):118.
115. Saag K.G., Teng G.G., Patkar N.M., Anuntiyo J., Finney C., Curtis J.R., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59:762-784.
116. Ledingham J., Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 2005, 44:157-163.
117. Wong G.H., Goeddel D.V. Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons. Nature 1986, 323:819-822.
118. Roux C.H., Brocq O., Breuil V., Albert C., Euller-Ziegler L. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) 2006, 45:1294-1297.
119. Anelli M.G., Torres D.D., Manno C., Scioscia C., Iannone F., Covelli M., et al. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis Rheum 2005, 52:2519-2520.
120. Ostuni P., Botsios C., Punzi L., Sfriso P., Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003, 62:686-687.
121. Peterson J.R., Hsu F.C., Simkin P.A., Wener M.H. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003, 62:1078-1082.
122. Parke F.A., Reveille J.D. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004, 51:800-804.
123. Zein N.N. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005, 42:315-322.
124. Aslanidis S., Vassiliadis T., Pyrpasopoulou A., Douloumpakas I., Zamboulis C. Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 2007, 26:261-264.
125. Magliocco M.A., Gottlieb A.B. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 2004, 51:580-584.
126. Zavos C., Kountouras J., Zavos N., Chatzopoulos D. Inhibition of tumour necrosis factor-alpha in patients with chronic hepatitis C infection. Clin Rheumatol 2007, 26:283.
127. Marotte H., Fontanges E., Bailly F., Zoulim F., Trepo C., Miossec P. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford) 2007, 46:97-99.
128. Cohen C.D., Horster S., Sander C.A., Bogner J.R. Kaposi's sarcoma associated with tumour necrosis factor alpha neutralising therapy. Ann Rheum Dis 2003, 62:684.
129. Vonkeman H., ten N.C., Rasker H., van de Laar M. Disseminated primary varicella infection during infliximab treatment. J Rheumatol 2004, 31:2517-2518.
130. Choi H.J., Kim M.Y., Kim H.O., Park Y.M. An atypical varicella exanthem associated with the use of infliximab. Int J Dermatol 2006, 45:999-1000.
131. Haerter G., Manfras B.J., de Jong-Hesse Y., Wilts H., Mertens T., Kern P., et al. Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis. Clin Infect Dis 2004, 39:e88-e94.
132. Aboulafia D.M., Bundow D., Wilske K., Ochs U.I. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc 2000, 75:1093-1098.
133. Sellam J., Bouvard B., Masson C., Rousiere M., Villoutreix C., Lacombe K., et al. Use of infliximab to treat psoriatic arthritis in HIV-positive patients. Jt Bone Spine 2007, 74:197-200.
134. Linardaki G., Katsarou O., Ioannidou P., Karafoulidou A., Boki K. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol 2007, 34:1353-1355.
135. Bartke U., Venten I., Kreuter A., Gubbay S., Altmeyer P., Brockmeyer N.H. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab. Br J Dermatol 2004, 150:784-786.
136. Beltran B., Nos P., Bastida G., Iborra M., Hoyos M., Ponce J. Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn's disease. Gut 2006, 55:1670-1671.
137. Kaur P.P., Chan V.C., Berney S.N. Successful etanercept use in an HIV-positive patient with rheumatoid arthritis. J Clin Rheumatol 2007, 13:79-80.
138. Fomin I., Caspi D., Levy V., Varsano N., Shalev Y., Paran D., et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006, 65:191-194.
139. Kapetanovic M.C., Saxne T., Nilsson J.A., Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford) 2007, 46:608-611.
140. Kapetanovic M.C., Saxne T., Sjoholm A., Truedsson L., Jonsson G., Geborek P. Influence of methotrexate. TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006, 45:106-111.
141. Visvanathan S., Keenan G.F., Baker D.G., Levinson A.I., Wagner C.L. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol 2007, 34:952-957.
142. Kaine J.L., Kivitz A.J., Birbara C., Luo A.Y. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007, 34:272-279.
143. Corbo M., Tay L., Leon F., Vratsanos G.A. Single dose of abatacept does not prevent the development of a positive immune response to tetanus and pneumococcal vaccines. Ann Rheum Dis 2006, 65(Suppl II):184.
144. Schiff M., Kaell A., Tay L., Vratsanos G., Bahrt K. Response to pneumococcal vaccine in rheumatoid arthritis patients with an inadequate response to anti-TNF therapy treated with abatacept in the ARRIVE trial. Ann Rheum Dis 2007, 66(Suppl II):437.
145. Oren S., Mandelboim M., Braun-Moscovici Y., Paran D., Ablin J., Litinsky I., et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 2008, 67:937-941.
146. Ghielmini M., Schmitz S.F., Cogliatti S.B., Pichert G., Hummerjohann J., Waltzer U., et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 2004, 103:4416-4423.
147. Bresnihan B., Alvaro-Gracia J.M., Cobby M., Doherty M., Domljan Z., Emery P., et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998, 41:2196-2204.
148. Cohen S., Hurd E., Cush J., Schiff M., Weinblatt M.E., Moreland L.W., et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:614-624.
149. Fleischmann R.M., Schechtman J., Bennett R., Handel M.L., Burmester G.R., Tesser J., et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003, 48:927-934.
150. Cohen S.B., Moreland L.W., Cush J.J., Greenwald M.W., Block S., Shergy W.J., et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004, 63:1062-1068.